Personalized combined modality therapy for locally advanced non-small cell lung cancer

D. Nathan Kim, Taek Keun Nam, Kevin S. Choe, Hak Choy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)74-84
Number of pages11
JournalCancer Research and Treatment
Volume44
Issue number2
DOIs
StatePublished - Jun 2012

Fingerprint

Combined Modality Therapy
Non-Small Cell Lung Carcinoma
Neoplasms
Therapeutics
Clinical Trials
Radiation
Drug Therapy

Keywords

  • Combined modality therapy
  • Epidermal growth factor receptor
  • Individualized medicine
  • Lung neoplasms
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Personalized combined modality therapy for locally advanced non-small cell lung cancer. / Nathan Kim, D.; Nam, Taek Keun; Choe, Kevin S.; Choy, Hak.

In: Cancer Research and Treatment, Vol. 44, No. 2, 06.2012, p. 74-84.

Research output: Contribution to journalArticle

Nathan Kim, D. ; Nam, Taek Keun ; Choe, Kevin S. ; Choy, Hak. / Personalized combined modality therapy for locally advanced non-small cell lung cancer. In: Cancer Research and Treatment. 2012 ; Vol. 44, No. 2. pp. 74-84.
@article{62d594da15cc4e2693a8b8c9750698c6,
title = "Personalized combined modality therapy for locally advanced non-small cell lung cancer",
abstract = "Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.",
keywords = "Combined modality therapy, Epidermal growth factor receptor, Individualized medicine, Lung neoplasms, Tyrosine kinase inhibitor",
author = "{Nathan Kim}, D. and Nam, {Taek Keun} and Choe, {Kevin S.} and Hak Choy",
year = "2012",
month = "6",
doi = "10.4143/crt.2012.44.2.74",
language = "English (US)",
volume = "44",
pages = "74--84",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "2",

}

TY - JOUR

T1 - Personalized combined modality therapy for locally advanced non-small cell lung cancer

AU - Nathan Kim, D.

AU - Nam, Taek Keun

AU - Choe, Kevin S.

AU - Choy, Hak

PY - 2012/6

Y1 - 2012/6

N2 - Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.

AB - Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.

KW - Combined modality therapy

KW - Epidermal growth factor receptor

KW - Individualized medicine

KW - Lung neoplasms

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84866904966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866904966&partnerID=8YFLogxK

U2 - 10.4143/crt.2012.44.2.74

DO - 10.4143/crt.2012.44.2.74

M3 - Article

VL - 44

SP - 74

EP - 84

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -